Invokana was introduced to the U.S. market in March 2013 and quickly became the go-to type 2 diabetes treatment, although the safety of the medication became a point of contention relatively quickly.
Invokana is a SGLT2 inhibitor that is prescribed along with diet and exercise to help improve glycemic control and lower blood sugar in adult patients with type 2 diabetes mellitus.
If left untreated, type 2 diabetes can lead to a number of serious health problems, including:
In May 2015, the FDA warned the public that canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance) may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization and could lead to death.
The FDA warned patients to pay close attention for signs of Ketoacidosis and to seek medical attention if they experienced any signs.
Following the warning issued in May 2015, the FDA reviewed the FDA Adverse Event Reporting System and identified 73 cases of ketoacidosis in patients with type 1 or type 2 diabetes.
As a result, the FDA followed up with a label change for Invokana, Farxiga and Jardiance in December 2015 which noted the risk of ketoacidosis.
In addition to diabetic ketoacidosis, there are several other serious and even potentially fatal side effects associated with Invokana, Farxiga and Jardiance, including:
In January 2016, the Institute for Safe Medication Practices released a report that highlighted potential concerns regarding a link between Invokana and kidney damage.
According to the report, both prescription volume and adverse drug event reports are increasing rapidly for canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance).
Lawsuits on behalf of individuals diagnosed with diabetic ketoacidosis continue to be filed against the manufacturers of the drugs, Janssen Pharmaceuticals, AstraZeneca and Boehringer Ingelheim.
Plaintiffs allege that they were not warned of the serious risk involved with taking Invokana, Farxiga or Jardiance.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
Weis Market Inc., a Mid-Atlantic food retailer based in Sunbury, Pennsylvania, has recalled its 48-ounce containers of Weis Quality Brownie Moose Tracks Ice Cream because the product may contain traces of egg, an allergen not declared on the ingredient statement label, according to the FDA.
Marlex Pharmaceuticals, Inc., of New Castle, Delaware, has announced a voluntary, consumer-level recall of one lot of Digoxin Tablets USP, 0125mg, as well as one lot of Digoxin Tablets USP, 0.25mg, because the labels of both products have been mixed up, according to the FDA.